v3.26.3
Recapitalization (Details)
$ / shares in Units, $ in Thousands
 9 Months Ended
Jul. 20, 2026
USD ($)
$ / shares
shares
Sep. 30, 2026
USD ($)
$ / shares
shares
Sep. 30, 2025
USD ($)
Jul. 19, 2026
$ / shares
shares
Jul. 13, 2026
$ / shares
shares
Dec. 31, 2025
shares
Reverse Recapitalization [Line Items]            
Net proceeds from Business Combination | $ $ 295,500 $ 295,490 $ 0      
Transaction costs | $ 15,200          
Proceeds from PCSC trust account, net of redemptions | $ 70,300          
Cash consideration | $ 400          
Gross proceeds from private investment in public entity | $ $ 240,000          
Number of shares issued in transaction (in shares) 24,000,000          
Share purchase price (in dollars per share) | $ / shares $ 10.00          
Total transaction costs | $ $ 25,700          
Accrued transaction costs | $ $ 10,500          
Percentage of ownership after transaction 63.00%          
Common stock, outstanding (in shares) 107,446,814 110,870,300       67,944,192
Issuance of common stock upon Business Combination and PIPE Financing, net of transaction costs (in shares) 32,920,769          
Common stock, outstanding shares held by former Legacy Freenome equity holders (in shares) 68,065,429          
Recapitalization exchange ratio 0.282895          
Warrants outstanding (in shares)   14,003   428,560    
Warrant exercise price (in dollars per share) | $ / shares   $ 4.85   $ 0.01 $ 0.01  
Number of securities called by warrants (in shares)       121,237 121,237  
Convertible Debt | Roche Convertible Debt            
Reverse Recapitalization [Line Items]            
Shares upon conversion (in shares) 6,460,616          
Common Shareholders            
Reverse Recapitalization [Line Items]            
Stock issued for acquisition (in shares) 6,478,269          
Sponsor Members            
Reverse Recapitalization [Line Items]            
Stock issued for acquisition (in shares) 2,442,500          
Perceptive Capital Solutions Corp.            
Reverse Recapitalization [Line Items]            
Common stock, outstanding (in shares)       8,920,769